Published in J Pharmacol Exp Ther on January 19, 2012
Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila) (2013) 1.01
Mechanistic and pharmacological issues of aspirin as an anticancer agent. Pharmaceuticals (Basel) (2012) 0.84
Circulating Prostaglandin Biosynthesis in Colorectal Cancer and Potential Clinical Significance. EBioMedicine (2015) 0.83
Circulating prostaglandins as biomarkers for colorectal cancer? EBioMedicine (2015) 0.75
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (2010) 13.13
APC mutations occur early during colorectal tumorigenesis. Nature (1992) 9.50
TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell (2008) 7.60
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 7.54
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med (2003) 4.88
Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med (2005) 4.57
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 4.16
Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood (2007) 3.38
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res (1980) 2.68
Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem (2004) 2.24
The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA (1999) 2.24
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur J Cancer (1995) 1.94
Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation (2005) 1.82
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther (1994) 1.79
Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol (2004) 1.76
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation (1983) 1.73
TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med (2005) 1.55
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest (2001) 1.45
Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol (1999) 1.43
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer (2004) 1.42
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene (2002) 1.42
Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res (2001) 1.39
The validation of self-reported smoking status by analysing cotinine levels in stimulated and unstimulated saliva, serum and urine. Oral Dis (2004) 1.31
Moderation of the platelet releasate response by aspirin. Blood (2007) 1.26
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res (2005) 1.23
Is cyclooxygenase-2 the alpha and the omega in cancer? J Clin Invest (2000) 1.22
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res (2002) 1.22
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J (2007) 1.20
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev (2010) 1.20
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol (2002) 1.13
Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. Methods Enzymol (2007) 1.07
The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis. J Lipid Res (2008) 1.04
Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Circ Res (2009) 1.04
The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation. FASEB J (2007) 0.91
Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis (1986) 0.91
Biopharmaceutical characterisation of a low-dose (75 mg) controlled-release aspirin formulation. Br J Clin Pharmacol (1993) 0.89
Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. Biochim Biophys Acta (1987) 0.86
Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.86
Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids (2005) 0.84
Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. J Natl Cancer Inst (1987) 0.80
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
A functional genomics strategy reveals Rora as a component of the mammalian circadian clock. Neuron (2004) 5.71
Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol (2011) 4.67
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
COX-2-derived prostacyclin confers atheroprotection on female mice. Science (2004) 2.87
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut (2013) 2.86
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol (2008) 2.82
Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation (2003) 2.77
Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation (2012) 2.76
Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation (2003) 2.69
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci (2007) 2.53
Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst (2006) 2.51
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest (2003) 2.27
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol (2005) 2.13
Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med (2012) 2.13
Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem (2007) 2.10
Prostanoids in health and disease. J Lipid Res (2008) 2.06
Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res (2004) 1.99
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.97
The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology (2009) 1.92
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation (2004) 1.88
COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol (2007) 1.77
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther (2006) 1.77
Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem (2003) 1.77
COX-2-dependent cardiac failure in Gh/tTG transgenic mice. Circ Res (2003) 1.72
Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med (2012) 1.71
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am J Pathol (2004) 1.71
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation (2002) 1.68
A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) (2011) 1.64
Genetic components of the circadian clock regulate thrombogenesis in vivo. Circulation (2008) 1.62
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum (2010) 1.61
Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem (2003) 1.60
Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem (2003) 1.57
The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res (2011) 1.56
Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther (2006) 1.53
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A (2006) 1.52
Circadian clocks and vascular function. Circ Res (2010) 1.52
Parecoxib, valdecoxib, and cardiovascular risk. Circulation (2005) 1.51
Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation (2008) 1.50
Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol (2002) 1.49
Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A (2002) 1.48
Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. Int J Cancer (2004) 1.42
Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function. Proc Natl Acad Sci U S A (2009) 1.41
Change in protein phenotype without a nucleus: translational control in platelets. Semin Thromb Hemost (2004) 1.41
Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation (2005) 1.40
Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation (2005) 1.40
Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res (2005) 1.38
COX-2-derived prostacyclin modulates vascular remodeling. Circ Res (2005) 1.37
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
EBP, a program for protein identification using multiple tandem mass spectrometry datasets. Mol Cell Proteomics (2006) 1.36
The role of tristetraprolin in cancer and inflammation. Front Biosci (Landmark Ed) (2012) 1.33
Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation (2005) 1.33
F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. Chem Phys Lipids (2004) 1.31
Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell (2012) 1.29
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology (2006) 1.27
Predictors of metachronous colorectal neoplasms in sporadic adenoma patients. Int J Cancer (2003) 1.24
The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip Rev RNA (2011) 1.24
Prevalence of adenomas and hyperplastic polyps in mismatch repair mutation carriers among CAPP2 participants: report by the colorectal adenoma/carcinoma prevention programme 2. J Clin Oncol (2008) 1.23
Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer (2009) 1.22
The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem (2001) 1.22
Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med (2012) 1.22
Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res (2007) 1.21
Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol (2007) 1.20
EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J (2007) 1.20
Training translators for smart drug discovery. Sci Transl Med (2010) 1.19
Recalibrating intellectual property rights to enhance translational research collaborations. Sci Transl Med (2012) 1.18
Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol (2004) 1.16
Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med (2005) 1.16
Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res (2013) 1.15